Overview

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)

Status:
Completed

Trial end date:
2003-02-01

Target enrollment:

Participant gender:

Summary

A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a course of therapy of 30 mg twice daily Lansoprazole.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dexlansoprazole
Esomeprazole
Lansoprazole